NEW YORK (GenomeWeb News) - Canadian biomarker developer Med BioGene has hired an investment advisory and financial services company and has granted some of its executives options to buy up to 560,000 common shares at Can$.34 ($.32) a share, the company said today.
 
The Vancouver, BC-based MBI said it has hired Peterson Capital, an investment, financial services, and communications firm, for a monthly cash rate and the option to buy up to 100,000 shares at Can$.34 a share.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.